Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer | Zendy

Emese Zsíros | Zendy; Sarah Lynam | Zendy; Kristopher Attwood | Zendy; Chong Wang | Zendy; Shanmuga Reddy Chilakapati | Zendy; Eduardo Cortes Gomez | Zendy; Song Liu | Zendy; Stacey N. Akers | Zendy; Shashikant Lele | Zendy; Peter J. Frederick | Zendy; Kunle Odunsi | Zendy

Open Access

Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer

Author(s) -

Emese Zsíros,

Sarah Lynam,

Kristopher Attwood,

Chong Wang,

Shanmuga Reddy Chilakapati,

Eduardo Cortes Gomez,

Song Liu,

Stacey N. Akers,

Shashikant Lele,

Peter J. Frederick,

Kunle Odunsi

Publication year - 2020

Publication title -

jama oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 8.846

H-Index - 99

eISSN - 2374-2445

pISSN - 2374-2437

DOI - 10.1001/jamaoncol.2020.5945

Subject(s) - medicine , pembrolizumab , bevacizumab , ovarian cancer , oncology , response evaluation criteria in solid tumors , cyclophosphamide , cancer , progressive disease , surgery , chemotherapy , immunotherapy

Treatment options for recurrent ovarian cancer are of limited clinical benefit and adversely affect patient quality of life, representing an unmet need for tolerable effective therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research